BioCentury | Apr 4, 2016
Clinical News

Darinaparsin: Phase II started

...Solasia began an open-label, Asian Phase II trial to evaluate 300 mg/m 2 IV darinaparsin once...
...65 patients. The company has exclusive, worldwide rights to develop and commercialize IV and oral darinaparsin...
...Meiji Seika Pharma Co. Ltd. , Tokyo, Japan Product: Darinaparsin ( SP-02 , ZIO-101 , SP-02L...
BioCentury | Sep 8, 2014
Company News

Ziopharm Oncology, Solasia deal

...2011 deal granting Solasia exclusive rights to develop and commercialize IV and oral darinaparsin ( ZIO-101...
...territories. Under the amended deal, Solasia now has exclusive, worldwide rights to develop and commercialize darinaparsin...
...therapeutics and immuno-oncology. In early 2015, Solasia expects to start an Asian pivotal trial of darinaparsin...
BioCentury | Nov 7, 2011
Clinical News

Zinapar darinaparsin: Phase I started

...began an open-label, Japanese Phase I trial to evaluate 200 and 300 mg/m 2 IV darinaparsin...
...relapsed or refractory PTCL. Solasia has exclusive rights from Ziopharm to develop and commercialize to darinaparsin...
...K.K. , Tokyo, Japan Ziopharm Oncology Inc. (NASDAQ:ZIOP), New York, N.Y. Product: Zinapar darinaparsin (ZIO-101, SP-02L...
BioCentury | May 16, 2011
Clinical News

Zinapar darinaparsin regulatory update

...The European Commission granted Orphan Drug designation for Ziopharm's Zinapar darinaparsin to treat peripheral T cell...
...indication. In March, Ziopharm granted Solasia exclusive rights to develop and commercialize IV and oral darinaparsin...
...Pharma K.K. , Tokyo, Japan Ziopharm Oncology Inc. (NASDAQ:ZIOP), New York, N.Y. Product: Zinapar darinaparsin (ZIO-101...
BioCentury | Mar 14, 2011
Finance

Still some pop in Benlysta

...week after granting Solasia Pharma K.K. exclusive rights to develop and commercialize IV and oral darinaparsin...
BioCentury | Mar 14, 2011
Finance

Highlights of weekly biotech stock moves

...week after granting Solasia Pharma K.K. exclusive rights to develop and commercialize IV and oral darinaparsin...
BioCentury | Mar 14, 2011
Company News

Solasia, Ziopharm Oncology deal

...Ziopharm granted Solasia exclusive rights to develop and commercialize IV and oral darinaparsin in 13 Asia-Pacific...
BioCentury | Mar 8, 2011
Company News

Ziopharm, Solasia in deal for darinaparsin

...granted Solasia Pharma K.K. (Tokyo, Japan) exclusive rights to develop and commercialize IV and oral darinaparsin...
BioCentury | Jan 31, 2011
Clinical News

Zinapar darinaparsin regulatory update

...The COMP issued a positive opinion to grant Orphan Drug designation for Ziopharm's Zinapar darinaparsin to...
...Medicines Agency (EMA). Ziopharm Oncology Inc. (NASDAQ:ZIOP), New York, N.Y. Product: Zinapar darinaparsin () ( ZIO-101...
BioCentury | Sep 27, 2010
Clinical News

Zinapar darinaparsin regulatory update

...FDA granted Orphan Drug designation for Ziopharm's Zinapar darinaparsin to treat peripheral T cell lymphoma (PTCL...
...cancer, lymphomas and advanced myeloma. Ziopharm Oncology Inc. (NASDAQ:ZIOP), New York, N.Y. Product: Zinapar darinaparsin (ZIO-101...
Items per page:
1 - 10 of 52